Literature DB >> 35972691

Circulating circular RNA hsa_circ_0023179 acts as a diagnostic biomarker for non-small-cell lung cancer detection.

Qi Zhang1,2, Shiyi Qin1,2, Chunlei Peng3, Yupeng Liu4, Yuejiao Huang5,6,7, Shaoqing Ju8.   

Abstract

BACKGROUND: Lung cancer, the most prevalent cancer-related death worldwide, still lacks the means for early diagnosis. Because of the unique properties of the loop that make it stable in body fluids, circular RNAs (circRNAs) as a biomarker becomes a possibility. This research purposed to explore whether hsa_circ_0023179 can be applied as a possible biomarker for the early diagnosis and prognosis of non-small cell lung cancer (NSCLC).
METHODS: hsa_circ_0023179 was screened by high-throughput sequencing of three pairs of NSCLC tissues and their surrounding tissues. Agarose gel electrophoresis (AGE), Sanger sequencing, exonuclease digestion assay, and actinomycin D were used to affirm the molecular properties of circRNA. Precision determination was performed by placement at room temperature and multiple freeze-thawing test for methodological evaluation. The expression of hsa_circ_0023179 in tissues, serum, and cells was determined by quantitative real-time polymerase chain reaction (qRT-PCR) to establish the receiver operating characteristic (ROC) curve to assess the diagnostic efficacy of hsa_circ_0023179.
RESULTS: hsa_circ_0023179 conforms to the basic properties of circRNA, and the detection method of hsa_circ_0023179 has good stability and repeatability. Its expression was connected to histological type, TNM stage, lymph node metastasis, and distal metastasis in NSCLC tissues, serum, and cells. Compared with traditional tumor markers with higher sensitivity and specificity. A combined diagnosis can significantly improve the diagnostic value. The decrease in postoperative expression level suggests some potential for dynamic monitoring.
CONCLUSION: hsa_circ_0023179 might be a promising novel serum marker for the detection and prediction of NSCLC.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biomarker; Diagnosis; Non-small-cell lung cancer; Prognosis; hsa_circ_0023179

Year:  2022        PMID: 35972691     DOI: 10.1007/s00432-022-04254-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  26 in total

1.  Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs.

Authors:  C Y Chen; P Sarnow
Journal:  Science       Date:  1995-04-21       Impact factor: 47.728

2.  Mis-splicing yields circular RNA molecules.

Authors:  C Cocquerelle; B Mascrez; D Hétuin; B Bailleul
Journal:  FASEB J       Date:  1993-01       Impact factor: 5.191

Review 3.  The biogenesis, biology and characterization of circular RNAs.

Authors:  Lasse S Kristensen; Maria S Andersen; Lotte V W Stagsted; Karoline K Ebbesen; Thomas B Hansen; Jørgen Kjems
Journal:  Nat Rev Genet       Date:  2019-08-08       Impact factor: 53.242

Review 4.  CircRNAs and cancer: Biomarkers and master regulators.

Authors:  Esther Arnaiz; Carla Sole; Lorea Manterola; Leire Iparraguirre; David Otaegui; Charles H Lawrie
Journal:  Semin Cancer Biol       Date:  2018-12-11       Impact factor: 15.707

Review 5.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

Review 6.  The expanding regulatory mechanisms and cellular functions of circular RNAs.

Authors:  Ling-Ling Chen
Journal:  Nat Rev Mol Cell Biol       Date:  2020-05-04       Impact factor: 94.444

7.  Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles.

Authors:  Orna Barash; Nir Peled; Fred R Hirsch; Hossam Haick
Journal:  Small       Date:  2009-11       Impact factor: 13.281

Review 8.  Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients.

Authors:  Florence de Fraipont; Sylvie Gazzeri; William C Cho; Beatrice Eymin
Journal:  Front Genet       Date:  2019-05-07       Impact factor: 4.599

Review 9.  Metabolomic Fingerprinting for the Detection of Early-Stage Lung Cancer: From the Genome to the Metabolome.

Authors:  Jean-François Haince; Philippe Joubert; Horacio Bach; Rashid Ahmed Bux; Paramjit S Tappia; Bram Ramjiawan
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

10.  circPTPN4 regulates myogenesis via the miR-499-3p/NAMPT axis.

Authors:  Bolin Cai; Manting Ma; Zhen Zhou; Shaofen Kong; Jing Zhang; Xiquan Zhang; Qinghua Nie
Journal:  J Anim Sci Biotechnol       Date:  2022-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.